Genetic variation associated with thyroid autoimmunity shapes the systemic immune response to PD-1 checkpoint blockade
Endocrinopathies, such as thyroid autoimmunity, are common among patients treated with immune checkpoint inhibitors. Here, by using a polygenic risk score (PRS) derived from a hypothyroidism GWAS, the authors show that cancer patients with high PRS are at increased risk of atezolizumab (anti-PD-L1)-...
Main Authors: | Zia Khan, Christian Hammer, Jonathan Carroll, Flavia Di Nucci, Sergio Ley Acosta, Vidya Maiya, Tushar Bhangale, Julie Hunkapiller, Ira Mellman, Matthew L. Albert, Mark I. McCarthy, G. Scott Chandler |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Portfolio
2021-06-01
|
Series: | Nature Communications |
Online Access: | https://doi.org/10.1038/s41467-021-23661-4 |
Similar Items
-
TIGIT-CD226-PVR axis: advancing immune checkpoint blockade for cancer immunotherapy
by: Ira Mellman, et al.
Published: (2022-04-01) -
527 Clonal hematopoiesis is associated with reduced response to immune checkpoint inhibitors in lung cancer
by: Ira Mellman, et al.
Published: (2023-11-01) -
449 Polygenic risk scores for liver injury are associated with the risk for autoimmune hepatitis in patients treated with atezolizumab
by: David Roe, et al.
Published: (2023-11-01) -
Whole genome sequencing across clinical trials identifies rare coding variants in GPR68 associated with chemotherapy-induced peripheral neuropathy
by: Zia Khan, et al.
Published: (2023-06-01) -
Allelic variation in HLA‐DRB1 is associated with development of antidrug antibodies in cancer patients treated with atezolizumab that are neutralizing in vitro
by: Christian Hammer, et al.
Published: (2022-06-01)